Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Oncolo-GISTIndependent statistical analysis of Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: Complete Statistical AnalysisIndependent statistical analysis of One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00580788).
- ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan: Complete Statistical AnalysisIndependent statistical analysis of ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ONTAKIndependent statistical analysis of A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- OPALINEIndependent statistical analysis of OPALINE : A Study Of Morbidity And Mortality At 2 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: Complete Statistical AnalysisIndependent statistical analysis of Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: primary endpoint results, effect estimate with…
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with…
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: Complete Statistical AnalysisIndependent statistical analysis of Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: primary endpoint results, effect estimate with confidence interval,…
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: primary endpoint results,…
- Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children: Complete Statistical AnalysisIndependent statistical analysis of Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT: Complete Statistical AnalysisIndependent statistical analysis of Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT: primary endpoint results, effect estimate with confidence interval, sample-size…
- Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach: Complete Statistical AnalysisIndependent statistical analysis of Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OPTISCREEN-BIndependent statistical analysis of Application of HBV Rapid Tests as a Tool for Wide-Use Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OPUSIndependent statistical analysis of the OPUS trial of cetuximab plus FOLFOX-4 versus FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer, including response, progression-free survival, overall survival, KRAS subgroup analyses, methodology, and…
- Oral Calcitriol With Ketoconazole in CRPC: Complete Statistical AnalysisIndependent statistical analysis of Oral Calcitriol With Ketoconazole in CRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03261336).
- Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL): Complete Statistical AnalysisIndependent statistical analysis of Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation: Complete Statistical AnalysisIndependent statistical analysis of Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Oral Pathology Asynchronous Telementoring Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Oral Pathology Asynchronous Telementoring Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04166214).
- Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma: Complete Statistical AnalysisIndependent statistical analysis of Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00301418).
- ORANGEIndependent statistical analysis of Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03717935).
- ORCHARRDIndependent statistical analysis of Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- OReOIndependent statistical analysis of A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ORIENT-1Independent statistical analysis of Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ORIENT-15Independent statistical analysis of ORIENT-15, the randomized phase 3 trial of sintilimab or placebo with chemotherapy in unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.
- ORIGAMAIndependent statistical analysis of Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ORKAIndependent statistical analysis of Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01866423).
- Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation: Complete Statistical AnalysisIndependent statistical analysis of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03414814).
- Oslo-CoMetIndependent statistical analysis of Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OsteosarcomaIndependent statistical analysis of Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01336803).
- OTT15-04Independent statistical analysis of Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the…
- OU-SCC-PI-4GIndependent statistical analysis of PARP Inhibition for Gliomas (PI-4G or π4g): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05297864).
- Outlook Quality of Life Intervention: Complete Statistical AnalysisIndependent statistical analysis of Outlook Quality of Life Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00784095).
- Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS: Complete Statistical AnalysisIndependent statistical analysis of Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01909141).
- Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter’s Syndrome, Refractory CLL and PLL: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00418093).
- Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PA.3An independent statistical analysis and educational interpretation of PA.3, a randomized phase 3 double-blind trial of Tarceva plus gemcitabine in patients with pancreatic cancer.
- PACEComplete statistical analysis of the randomized phase 2 PACE trial evaluating palbociclib-based treatment after CDK and endocrine therapy in metastatic breast cancer, including PFS, response, statistical methodology, safety, and interpretation.
- PACIFICComplete statistical analysis of the PACIFIC phase 3 trial of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer, including primary endpoints, time-to-event methods, secondary analyses, safety,…